Healthcare / BiotechnologyNasdaqGS
$2.83
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.4M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$164M
P/E
10.5x
↓EV/EBITDA
18.1x
↑ROE
14.5%
↑Gross Margin
N/A
•Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-21.2%
FCF / Net income
-1.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $59.6M · net income $8.6M · FCF $-12.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $59.6M | $59.6M | $27.4M | $96.7M | $48.6M | $3.1M | $258000.00 | $4.7M | $4.0M | $2.0M | $335000.00 | — |
| Net Income | $8.6M | $8.6M | $-68.6M | $22.8M | $-46.4M | $-89.8M | $-78.3M | $-60.9M | $-41.7M | $-38.7M | $-25.5M | $-10.2M |
| EBITDA | $7.2M | $7.2M | $-72.5M | $27.2M | $-42.9M | $-87.3M | $-78.4M | $-62.5M | $-42.4M | $-41.4M | $-32.9M | $-13.3M |
| EPS | 0.15 | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 | — | — | — | — | — | — |
| Operating Margin | 12.0% | 12.0% | -264.6% | 27.7% | -62.9% | -2865.5% | -30664.0% | -1333.1% | -1079.3% | -2108.6% | -9916.7% | — |
| Net Margin | 14.4% | 14.4% | -250.3% | 23.6% | -95.5% | -2925.1% | -30348.8% | -1284.3% | -1051.4% | -1957.7% | -7609.3% | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.05 | 0.05 | 0.09 | 0.05 | 0.09 | — | — | — | — | — | — | — |
| Current Ratio | 10.50 | 10.50 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-12.6M | $-12.6M | $-23.4M | $-33.0M | $-7.7M | — | $-86.0M | $-50.3M | $-42.1M | $-39.1M | $-29.8M | — |
| Returns | ||||||||||||
| ROE | 14.5% | 14.5% | -148.7% | 21.3% | -61.1% | -101.7% | -59.3% | -81.7% | -36.1% | -45.8% | 56.1% | — |
| Valuation | ||||||||||||
| P/E | 10.48 | 10.48 | — | 3.33 | — | — | — | — | — | — | — | — |
| EV/EBITDA | 18.12 | 18.12 | — | 0.18 | — | — | — | — | — | — | — | — |
| P/B | 2.83 | 2.83 | 1.29 | 0.71 | 0.89 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | 117.6% | 117.6% | -71.7% | 99.1% | — | 1089.9% | -94.6% | 19.6% | 100.4% | 490.7% | — | — |
| EPS Growth | 111.8% | 111.8% | -395.3% | 135.0% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
18.7%
EPS terminal req.
$0.25
Spread vs growth
93.1%
5Y implied EPS CAGR
15.2%
EPS terminal req.
$0.30
Spread vs growth
96.6%
10Y implied EPS CAGR
12.6%
EPS terminal req.
$0.49
Spread vs growth
99.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.27 → 0.15
Residual
+13.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.